臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

Jump to a point in the index:
Or type in a year:

Show Most Recent First

Ordering With Oldest First

Showing items 2261091-2261115 of 2349070 (93963 Page(s) Totally)
<< < 90439 90440 90441 90442 90443 90444 90445 90446 90447 90448 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
國立交通大學	2022-02-21T00:24:27Z	【教師專訪】黃敬群教授：學無止境，勇於創新	高儷玲
國立交通大學	2022-02-21T00:24:27Z	【資訊系友】蔡祈岩學長：正面的態度讓你哪裡都是舒適圈	高儷玲
國立交通大學	2022-02-21T00:24:27Z	【科普軼聞】從水流星到洲際飛彈導航科技發展史	林一平/交大講座教授
國立交通大學	2022-02-21T00:24:27Z	【Industry Collaboration Project】NCTU: The First-open Source 5G Core Network Launches	高儷玲
臺大學術典藏	2022-02-21T02:04:29Z	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia	Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; Lu Y.-S.; Chuang E.Y.; Thiery J.P.; Huang C.-S.; ANN-LII CHENG
臺大學術典藏	2022-02-21T02:04:31Z	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-�eB-related signaling	Kuo S.-H.; Yang S.-H.; Wei M.-F.; Lee H.-W.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2022-02-21T02:04:31Z	APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	Lau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M.
臺大學術典藏	2022-02-21T02:04:32Z	Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients	Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; ANN-LII CHENG; Lu Y.-S.
臺大學術典藏	2022-02-21T02:04:32Z	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma	Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I.
臺大學術典藏	2022-02-21T02:04:32Z	Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study	Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J.
臺大學術典藏	2022-02-21T02:04:33Z	Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma	Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F.
臺大學術典藏	2022-02-21T02:04:33Z	Evolution of systemic treatment for advanced hepatocellular carcinoma	Wu T.-C.; Shen Y.-C.; ANN-LII CHENG
臺大學術典藏	2022-02-21T02:04:33Z	Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort	Chen K.-H.; Lin L.-I.; Yuan C.-T.; Tseng L.-H.; Chao Y.-L.; Liang Y.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2022-02-21T02:04:34Z	Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma	Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG; Lin Z.-Z.
臺大學術典藏	2022-02-21T02:04:34Z	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial	Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M.
臺大學術典藏	2022-02-21T02:04:35Z	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma	Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C.
臺大學術典藏	2022-02-21T02:04:35Z	Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study	Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG
臺大學術典藏	2022-02-21T02:04:35Z	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT	Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H.
臺大學術典藏	2022-02-21T02:04:35Z	Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial	Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y.
臺大學術典藏	2022-02-21T02:04:36Z	Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages	Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C.
臺大學術典藏	2022-02-21T02:04:36Z	Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy	Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2022-02-21T02:51:54Z	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study	Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J.
臺大學術典藏	2022-02-21T02:51:54Z	Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy	YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L.
臺大學術典藏	2022-02-21T02:51:55Z	Evolution of systemic treatment for advanced hepatocellular carcinoma	Wu T.-C.; YING-CHUN SHEN; Cheng A.-L.
臺大學術典藏	2022-02-21T03:52:30Z	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC	Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H.

Showing items 2261091-2261115 of 2349070 (93963 Page(s) Totally)
<< < 90439 90440 90441 90442 90443 90444 90445 90446 90447 90448 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| Total items :0
	Visitors : 53025794 Online Users : 840 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library